文献速递骨显像与常规 SPECT肿瘤 PET/CT

18F-氟化钠PET/CT对骨显像正常的前列腺癌患者骨转移检测无附加价值

No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy.
PubMed 文献 · J Nucl Med · 2019-05-30

结果显示75例(93%)达生化缓解、6例生化失败,NaF PET/CT仅1例(1.2%)提示骨转移,所有生化失败者NaF PET/CT与骨显像均为阴性。结论认为在骨显像正常的中高危前列腺癌患者中,NaF PET/CT对骨分期无附加价值。

要点

  • 骨显像正常的中高危前列腺癌患者中,NaF PET/CT仅1例(1.2%)提示骨转移。
  • NaF PET/CT提示骨转移或结果不确定的8例患者均出现生化缓解。
  • 全部生化失败患者的NaF PET/CT与骨显像均未见骨转移。

核心结论

  • 在骨显像正常、拟行前列腺切除术的中危或高危前列腺癌患者中,额外NaF PET/CT对骨分期无附加价值。

研究设计与样本

  • 生化缓解定义为术后6周和6个月PSA<0.2 ng/mL,PSA≥0.2 ng/mL为生化失败。

主要发现

  • 75例(93%)达生化缓解,6例出现生化失败。
  • NaF PET/CT示骨转移1例(1.2%)、结果不确定7例(8.6%)、无骨转移73例(90.1%)。
  • NaF PET/CT示骨转移或结果不确定的8例患者均出现生化缓解。
  • 全部生化失败患者的NaF PET/CT与骨显像均未见骨转移。

关键数值与推荐

  • 生化缓解:术后6周和6个月PSA<0.2 ng/mL;生化失败:PSA≥0.2 ng/mL。
  • NaF PET/CT结果分布:骨转移1例(1.2%)、不确定7例(8.6%)、无骨转移73例(90.1%)。

临床怎么用

  • 对骨显像正常、拟行前列腺切除术的中高危前列腺癌患者,不必常规加做NaF PET/CT进行骨分期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this study was to determine if additional 18F-sodium fluoride PET/CT (NaF PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels < 0.2 ng/mL at 6 wk and 6 mo postoperatively, PSA level ≥ 0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; 75 patients (93%) achieved biochemical responses, 6 patients had biochemical failure. NaF PET/CT indicated bone metastasis in 1 patient (1.2%), was equivocal in 7 patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zacho HD, Jochumsen MR, Langkilde NC, et al. No Added Value of 18F-Sodium Fluoride PET/CT for the Detection of Bone Metastases in Patients with Newly Diagnosed Prostate Cancer with Normal Bone Scintigraphy. J Nucl Med. 2019. PMID: 31147402. doi:10.2967/jnumed.119.229062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。